Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 5Gynecologic 5Gastrointestinal 5Breast 4Sarcoma 3Genitourinary 3Tumor-Agnostic 2Plasma cell 1Other solid neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Prostatic Neoplasms 3Breast Neoplasms 1Bone Neoplasms 1Bone Diseases 1

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × saracatinib × Genitourinary × Clear all
NCT00513071 2018-04-19

AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

National Cancer Institute (NCI)

Phase 2 Completed
28 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT01267266 2015-04-01

Saracatinib in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
31 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

NCT00558272 2013-05-27

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

AstraZeneca

Phase 2 Completed
139 enrolled 23 charts
BreastGenitourinarySarcoma

Bone Diseases, Bone Neoplasms, Breast Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡